| Home | Article Database | Resources | Tools & Just for Fun | Search HY |
Peyronie's disease, a condition of uncertain cause, is characterized by a plaque, or hard lump, that forms on the penis. The plaque develops on the upper or lower side of the penis in layers containing erectile tissue. It begins as a localized inflammation and can develop into a hardened scar.
Cases of Peyronie's disease range from mild to severe. Symptoms may
develop slowly or appear overnight. In severe cases, the hardened plaque
reduces flexibility, causing pain and forcing the penis to bend or arc
during erection. In many cases, the pain decreases over time, but the
bend in the penis may remain a problem, making sexual intercourse difficult.
The sexual problems that result can disrupt a couple's physical and
emotional relationship and lead to lowered self-esteem in the man. In
a small percentage of patients with the milder form of the disease, inflammation
may resolve without causing significant pain or permanent bending.
The plaque itself is benign, or noncancerous. A plaque on the top of the shaft (most common) causes the penis to bend upward; a plaque on the underside causes it to bend downward. In some cases, the plaque develops on both top and bottom, leading to indentation and shortening of the penis. At times, pain, bending, and emotional distress prohibit sexual intercourse.
One study found Peyronie's disease occurring in 1 percent of men. Although the disease occurs mostly in middle-aged men, younger and older men can acquire it. About 30 percent of people with Peyronie's disease develop fibrosis (hardened cells) in other elastic tissues of the body, such as on the hand or foot. A common example is a condition known as Dupuytren's contracture of the hand. In some cases, men who are related by blood tend to develop Peyronie's disease, which suggests that familial factors might make a man vulnerable to the disease.
Men with Peyronie's disease usually seek medical attention because of painful erections and difficulty with intercourse. Since the cause of the disease and its development are not well understood, doctors treat the disease empirically; that is, they prescribe and continue methods that seem to help. The goal of therapy is to keep the Peyronie's patient sexually active. Providing education about the disease and its course often is all that is required. No strong evidence shows that any treatment other than surgery is effective. Experts usually recommend surgery only in long-term cases in which the disease is stabilized and the deformity prevents intercourse.
A French surgeon, François de la Peyronie, first described Peyronie's disease in 1743. The problem was noted in print as early as 1687. Early writers classified it as a form of impotence, now called erectile dysfunction (ED). Peyronie's disease can be associated with ED; however, experts now recognize ED as only one factor associated with the disease--a factor that is not always present.
Course of the Disease
Many researchers believe the plaque of Peyronie's disease develops following trauma (hitting or bending) that causes localized bleeding inside the penis. Two chambers known as the corpora cavernosa run the length of the penis. The inner-surface membrane of the chambers is a sheath of elastic fibers. A connecting tissue, called a septum, runs along the center of each chamber and attaches at the top and bottom.
If the penis is abnormally bumped or bent, an area where the septum attaches to the elastic fibers may stretch beyond a limit, injuring the lining of the erectile chamber and, for example, rupturing small blood vessels. As a result of aging, diminished elasticity near the point of attachment of the septum might increase the chances of injury.
The damaged area might heal slowly or abnormally for two reasons: repeated trauma and a minimal amount of blood flow in the sheath-like fibers. In cases that heal within about a year, the plaque does not advance beyond an initial inflammatory phase. In cases that persist for years, the plaque undergoes fibrosis, or formation of tough fibrous tissue, and even calcification, or formation of calcium deposits.
While trauma might explain acute cases of Peyronie's disease, it does not explain why most cases develop slowly and with no apparent traumatic event. It also does not explain why some cases disappear quickly, and why similar conditions such as Dupuytren's contracture do not seem to result from severe trauma.
Some researchers theorize that Peyronie's disease may be an autoimmune disorder.
A number of drugs list Peyronie's disease as a possible side effect. Most of these drugs belong to a class of blood pressure and heart medications called beta blockers. One beta blocker is an eye drop preparation used to treat glaucoma. Other drugs that may cause Peyronie's disease are interferon, used to treat multiple sclerosis, and phenytoin, an anti-seizure medicine. The chances of developing Peyronie's disease from any of these medicines are very low. Patients should check with their doctor before discontinuing any prescribed drug.
Because the course of Peyronie's disease
is different in each patient and because some patients experience improvement
without treatment, medical experts suggest waiting 1 to 2 years or longer
before attempting to correct it surgically. During that wait, patients often
are willing to undergo treatments whose effectiveness has not been proven.
Some researchers have given men with Peyronie's disease vitamin E orally in small-scale studies and have reported improvements. Yet, no controlled studies have established the effectiveness of vitamin E therapy. Similar inconclusive success has been attributed to oral application of para-aminobenzoate, a substance belonging to the family of B-complex molecules.
Researchers have injected chemical agents such as verapamil, collagenase,
steroids, and calcium channel blockers directly into the plaques. These
interventions are still considered unproven because studies have included
low numbers of patients and have lacked adequate control groups. Steroids,
such as cortisone, have produced unwanted side effects, such as the atrophy or death
of healthy tissues. Another intervention involves iontophoresis, the use
of a painless current of electricity to deliver verapamil or some other agent
under the skin to the plaque.
Radiation therapy, in which high-energy rays are aimed at the plaque,
has also been used. Like some of the chemical treatments, radiation appears
to reduce pain, but it has no effect at all on the plaque itself and can cause unwelcome
side effects. Although the variety of agents and methods used points to
the lack of a proven treatment, new insights into the wound
healing process may yield more effective therapies in the near future.
Peyronie's disease has been treated with some success by surgery. The two most common surgical methods are removal or expansion of the plaque followed by placement of a patch of skin or artificial material, and removal or pinching of tissue from the side of the penis opposite the plaque, which cancels out the bending effect. The first method can involve partial loss of erectile function, especially rigidity. The second method, known as the Nesbit procedure, causes a shortening of the erect penis.
Some men choose to receive an implanted device that increases rigidity of the penis. In some cases, an implant alone will straighten the penis adequately. In other cases, implantation is combined with a technique of incisions and grafting or plication (pinching or folding the skin) if the implant alone does not straighten the penis.
Most types of surgery produce positive results. But because complications can occur, and because many of the phenomena associated with Peyronie's disease (for example, shortening of the penis) are not corrected by surgery, most doctors prefer to perform surgery only on the small number of men with curvature so severe that it prevents sexual intercourse.
For More Information
American Foundation for Urologic Disease
1128 North Charles Street
Baltimore, MD 21201
Phone: 1-800-242-2383 or (410) 468-1800
National Organization for Rare Disorders
P.O. Box 8923
New Fairfield, CT 06812-8923
National Kidney and Urologic Diseases Information Clearinghouse
3 Information Way
Bethesda, MD 20892-3580
Phone: 1-800-891-5390 or (301) 654-4415
The National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC)
is a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK is part of the National Institutes of Health under the U.S. Department of Health and Human Services. Established in 1987, the clearinghouse provides information
about diseases of the kidneys and urologic system to people with kidney and urologic disorders and to their families, health care professionals, and the public. NKUDIC answers inquiries, develops and distributes publications, and works closely with professional and patient organizations and Government agencies to coordinate resources about kidney and urologic diseases.
Publications produced by the clearinghouse are carefully reviewed by both NIDDK scientists and outside experts.
This e-text is not copyrighted. The clearinghouse encourages users of this e-pub to duplicate and distribute as many copies as desired.
NIH Publication No. 01-3902
Posted: February 1998
Updated: September 2001